Get the Stockscreener App
5.81
4.60%
-0.28
After Hours:
5.83
0.02
+0.34%
Entrada Therapeutics Inc stock is traded at $5.81, with a volume of 126.45K.
It is down -4.60% in the last 24 hours and up +10.04% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$6.09
Open:
$6.17
24h Volume:
126.45K
Relative Volume:
0.48
Market Cap:
$221.00M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
1.9628
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
-1.86%
1M Performance:
+10.04%
6M Performance:
-26.46%
1Y Performance:
-65.38%
1-Day Range:
$5.792
$6.17
1-Week Range:
$5.792
$6.90
52-Week Range:
$4.93
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
5.81 | 231.65M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
Applying sector rotation models to Entrada Therapeutics Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - newser.com
Technical analysis overview for Entrada Therapeutics Inc. stockChart Signals & High Conviction Buy Zone Picks - newser.com
Best data tools to analyze Entrada Therapeutics Inc. stockJuly 2025 Retail & Verified Chart Pattern Trade Signals - newser.com
Sector ETF performance correlation with Entrada Therapeutics Inc.2025 Trading Recap & Consistent Growth Stock Picks - newser.com
Is it time to cut losses on Entrada Therapeutics Inc.July 2025 Opening Moves & Consistent Income Trade Ideas - newser.com
Signal strength of Entrada Therapeutics Inc. stock in tech scanners2025 Geopolitical Influence & Advanced Technical Analysis Signals - newser.com
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st
Entrada Therapeutics (NASDAQ:TRDA) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
H.C. Wainwright maintains $20 target on Entrada Therapeutics stock - MSN
Analysts Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) Target Price at $25.67 - Defense World
What’s next for Entrada Therapeutics Inc. stock priceStop Loss & Weekly Sector Rotation Insights - newser.com
What high frequency data says about Entrada Therapeutics Inc.Weekly Trend Report & Daily Chart Pattern Signals - newser.com
How to forecast Entrada Therapeutics Inc. trends using time series2025 Institutional Moves & Weekly Breakout Stock Alerts - newser.com
Can swing trading help recover from Entrada Therapeutics Inc. lossesTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Statistical indicators supporting Entrada Therapeutics Inc.’s strengthMarket Trend Summary & Growth Focused Entry Reports - newser.com
Why Entrada Therapeutics Inc. stock is in analyst buy zone2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
Entrada Therapeutics Inc Stock Analysis and ForecastMarket Rumors and News & Free Trading Psychology Coaching - earlytimes.in
What analysts say about Entrada Therapeutics Inc stockStochastic Oscillator Alerts & Exceptional Capital Trading - earlytimes.in
How Regulatory Changes Could Impact JITF Infralogistics Limited’s BusinessSector Performance Review & Buy Sell Signal Notifications - earlytimes.in
Should you hold or exit Entrada Therapeutics Inc. nowCEO Change & Fast Momentum Stock Entry Tips - newser.com
What drives Entrada Therapeutics Inc stock priceShort Interest Overview & Connect With Bulls, Avoid the Bears - Early Times
Is Entrada Therapeutics Inc. stock a top momentum playJuly 2025 Big Picture & Expert Verified Stock Movement Alerts - The British Mountaineering Council
Transcript : Entrada Therapeutics, Inc.Special Call - MarketScreener
Using Ichimoku Cloud for Entrada Therapeutics Inc. technicalsQuarterly Earnings Summary & Reliable Momentum Entry Alerts - newser.com
Goldman Sachs Group Inc. Has $837,000 Stock Holdings in Entrada Therapeutics, Inc. $TRDA - Defense World
How institutional ownership impacts Entrada Therapeutics Inc. stockProfit Target & Accurate Intraday Trading Signals - newser.com
Strs Ohio Acquires New Shares in Entrada Therapeutics, Inc. $TRDA - Defense World
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entrada Therapeutics Inc Stock (TRDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| 5AM Ventures V, L.P. | 10% Owner |
Jul 09 '25 |
Sale |
7.50 |
20,065 |
150,528 |
3,163,066 |
| 5AM Ventures V, L.P. | 10% Owner |
Jul 09 '25 |
Sale |
7.50 |
6,935 |
52,026 |
1,093,313 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):